For decades, cancer screening has relied on multiple tests — mammograms for breast cancer, colonoscopies for colorectal cancer, Pap smears for cervical cancer, and low-dose CT scans for lung cancer. While these methods save lives, many deadly cancers still have no routine screening options.
A new generation of technology aims to change that with a single blood sample.
Scientists have developed Multi-Cancer Early Detection (MCED) blood tests capable of identifying signals from more than 50 different cancers before symptoms even appear. The technology has the potential to become one of the biggest breakthroughs in preventive medicine in decades. (Galleri® Test)
What Is a Multi-Cancer Blood Test?
Unlike traditional cancer screening methods that search for one specific cancer, MCED tests analyze tiny fragments of DNA released by tumors into the bloodstream, known as circulating tumor DNA (ctDNA).
Using advanced machine learning algorithms and genomic analysis, these tests search for molecular signatures associated with cancer and can often identify where in the body the cancer originated. (AAFP)
One of the most well-known examples is the Galleri Test, developed by GRAIL, which can detect signals associated with more than 50 cancer types using a single blood draw. (Galleri® Test)
Why This Matters
Many cancers become deadly because they are discovered too late.
Today, routine screening exists for only a handful of cancers:
Breast cancer
Cervical cancer
Colorectal cancer
Lung cancer (for high-risk individuals)
Prostate cancer in selected cases
However, some of the deadliest cancers — including pancreatic, ovarian, liver, esophageal, and certain blood cancers — often remain undetected until symptoms appear and treatment options become limited. MCED tests aim to close this gap. (OHSU)
How the Test Works
The process is surprisingly simple:
A patient provides a standard blood sample.
The laboratory extracts fragments of cell-free DNA circulating in the blood.
Artificial intelligence models analyze DNA methylation patterns and other biomarkers.
If a cancer signal is detected, the system predicts the most likely organ or tissue where the cancer originated.
Doctors then perform additional diagnostic tests to confirm the finding. (AAFP)
How Accurate Is It?
The results are promising but not perfect.
Studies show the technology can identify cancer signals from more than 50 cancers while maintaining a very low false-positive rate of approximately 0.4% to 0.5% among people without cancer. (Galleri® Test)
For cancers that account for most cancer deaths, detection performance is significantly higher than average. Some studies reported sensitivities exceeding 70% for the deadliest cancers when used alongside existing screening programs. (GRAIL)
However, overall detection rates vary considerably depending on cancer type and stage. The tests generally perform better for advanced cancers than for very early-stage tumors. (ASCO)
The Challenges Scientists Are Still Solving
Despite the excitement, experts caution against viewing these tests as a replacement for traditional screening.
Recent large clinical trials involving more than 140,000 participants showed encouraging reductions in some advanced cancers but failed to meet their primary goal of significantly reducing all late-stage diagnoses across the population. Researchers believe additional studies are needed before widespread adoption becomes standard healthcare practice. (The Guardian)
Key challenges include:
Missing some early-stage cancers.
False negatives creating false reassurance.
Determining the best age and frequency for testing.
Managing follow-up procedures after positive results.
Reducing costs to improve accessibility. (AJMC)
AI Is the Engine Behind the Revolution
Artificial intelligence plays a central role in MCED testing.
Modern AI models analyze millions of genomic patterns that would be impossible for humans to interpret manually. As more patient data becomes available, these systems are expected to improve their ability to identify cancer earlier and more accurately.
Future generations of AI-powered screening may combine:
Medical imaging
Electronic health records
Together, these technologies could enable truly personalized preventive healthcare. (PMC)
What Happens Next?
Researchers envision a future annual health check that includes:
Blood pressure measurement
Cholesterol testing
Diabetes screening
A multi-cancer blood test
Instead of waiting for symptoms to appear, medicine may shift toward identifying disease years before it becomes dangerous.
Several countries are already conducting national-scale trials to determine whether these tests improve survival rates and reduce healthcare costs. The coming decade may determine whether MCED screening becomes as routine as today's cholesterol tests. (Clinical Lab Products)
Conclusion
The idea of detecting more than 50 cancers from a single blood sample once sounded like science fiction.
Today, it is becoming reality.
While the technology still faces scientific and regulatory hurdles, multi-cancer early detection tests represent one of the most exciting developments in modern medicine. If ongoing trials continue to show benefits, future generations may look back at symptom-based cancer diagnosis as a relic of the past.
The race to detect cancer before it starts winning may have already begun. (PMC)